Founded in January of 2020, VREX Therapeutics is built upon the ground-breaking science of Prof. Dr. Feng Yao,  out of Harvard Medical School and Brigham and Women's Hospital.  VREX Therapeutics is driven to create new immunotherapy drugs that assist in treating and curing solid tumor cancers.

Biotechnology

VREX Therapeutics

Andrew F. Sandford

Q. Karen Zhu

Feng Yao

The founding team at VREX Therapeutics has a history of experience in the biotech industry, with a focus on strategic planning and investment. The team has also been involved with various startups, including ElevateBio and Nature's Toolbox (NTx). In addition, the team has also been involved with Anzu Partners as an Executive In Residence.

Founding Team

About

Team members

Other teams at VREX Therapeutics

Leadership Team

Board of Directors